Indication
For treatment of mild cognitive impairment and mild dementia due to Alzheimer’s disease in adult patients that are apolipoprotein E ɛ 4 (ApoEɛ4) heterozygotes or non-carriers.
Medicine details
- Medicine name:
- lecanemab (Leqembi)
- SMC ID:
- SMC2811
- Pharmaceutical company
- Eisai Ltd
- BNF chapter
- Central nervous system
- Submission type
- Resubmission
- Publication due date:
- 07 July 2025
- SMC meeting date:
- 03 June 2025